ASLAN Pharmaceuticals announced that the FDA has granted ASLAN003 Orphan Drug Designation, or ODD, as a treatment for acute myeloid leukaemia, or AML. ASLAN003 is an orally active, potent inhibitor of human dihydroorotate dehydrogenase that has the potential to be first-in-class in AML. AML is a cancer of the myeloid line of blood cells, characterised primarily by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.